• moistclump@lemmy.world
    link
    fedilink
    arrow-up
    2
    ·
    3 months ago

    Interesting. Wonder why they wouldn’t release the letter from the FDA for a more full discussion:

    In an e-mail to Nature, Lykos declined to provide the complete letter detailing the agency’s specific concerns and directed the news team instead to its release. Experts say that without access to the letter, it’s hard to determine why the FDA reached the decision it did. “We really are going off incomplete information,” says Mason Marks, who studies drug policy at Florida State University in Tallahassee, adding that he was “a little surprised” by the agency’s decision.